|1.||Favier, Anne-Laure: 2 articles (01/2011 - 01/2010)|
|2.||Perino, Julien: 2 articles (01/2011 - 01/2010)|
|3.||Debouzy, Jean-Claude: 2 articles (01/2011 - 01/2010)|
|4.||Crouzier, David: 2 articles (01/2011 - 01/2010)|
|5.||Janshoff, Andreas: 2 articles (10/2004 - 03/2002)|
|6.||Mady, Mohsen Mahmoud: 1 article (04/2015)|
|7.||Elbialy, Nihal Saad: 1 article (04/2015)|
|8.||McGarry, Ronald C: 1 article (12/2014)|
|9.||Anderson, Kimberly W: 1 article (12/2014)|
|10.||Hilt, J Zach: 1 article (12/2014)|
08/17/2010 - "DPPG-FTL-ZOL is significantly more efficient at intracellular delivery of ZOL than PEG-FTL-ZOL in FR-expressing tumor cells."
08/17/2010 - "The uptake of ZOL by FR-expressing tumor cells was enhanced approximately 25-fold with DPPG-FTL-ZOL, and only approximately 4-fold with PEG-FTL-ZOL. "
01/01/1996 - "Vesicle material accumulation in A-431 tumors, xenotransplanted in nude mice, after 30 min of local hyperthermia (42 degrees C) is 4-fold higher for the DPPC/ELA (1/2), 2.8-fold higher for the DPPC/DPPG/EL-OH (0.8/0.2/2) and 3.7-fold higher for the DPPC/ELA/EL-OH (1/1/1) mixtures than for similar vesicles used at the physiological temperature. "
08/01/1992 - "Uptake of DPPG was compared in normal, diabetic, tumor-bearing and heparin pretreated rats, revealing differences in uptake and clearance of radioactivity, correlating with hepatic lipase activity of these groups. "
12/04/1996 - "Under comparable conditions phosphatidylglycerol (DPPG)-containing or dicetyl phosphate (DCP)-containing liposomes did not inhibit or only marginally inhibited the induction of tumor cytotoxicity. "
|2.||Dehydration (Water Stress)
09/15/2003 - "Film compression along the transition region provokes the dehydration of polar groups and subsequent change of their conformation, thus causing the DPPG molecules to emerge up to the interface. "
10/01/1991 - "All these observations are rationalized by the following model: adjacent bilayers of DPPG are bridged by tetramers of melittin through electrostatic interactions inducing surface charge neutralization and partial dehydration of the complexes. "
03/18/2003 - "The aim of the present study was to evaluate the efficiency of human polyvalent intravenous immunoglobulins (IVIG) when protected after encapsulation within EPC: DPPG liposomes by dehydration/rehydration. "
|4.||Lung Neoplasms (Lung Cancer)
12/01/2014 - "In vitro cellular characterization on lung cancer cells demonstrated the enhanced chemotherapeutic cytotoxic activity of paclitaxel from co-spray-dried DPPC/DPPG (co-SD DPPC/DPPG) lung surfactant-based carrier particles and the cytotoxicity of the particles via pulmonary cell viability analysis, fluorescent microscopy imaging, and transepithelial electrical resistance (TEER) testing at air-interface conditions. "
12/01/2014 - "High-performing dry powder inhalers of paclitaxel DPPC/DPPG lung surfactant-mimic multifunctional particles in lung cancer: physicochemical characterization, in vitro aerosol dispersion, and cellular studies."
08/01/2013 - "The adsorption kinetic curves of DPPG liposomes onto a low-roughness PAH layer reveal an adsorbed amount of 5 mg/m², pointing to liposome rupture, whereas a high-roughness surface leads to adsorbed amounts of 51 mg/m², signifying adsorption of intact liposomes. "
10/01/2004 - "Vesicles composed of DPPG/DPPC were less susceptible to deformation and rupture, a fact that can be attributed to the higher bending rigidity of DPPG/DPPC liposomes. "
10/01/2004 - "More than 70 mol% of DPPG were needed to induce adhesion-controlled rupture of surface-attached vesicles, while only 30-50% of POPG were sufficient to form planar lipid bilayers on the quartz."
03/01/2002 - "We propose that the preferential interaction between SP-B and negatively charged DPPG leads to accumulation of negative charges in particular regions, causing strong adhesion between DPPG-containing vesicles and the monolayer mediated by Ca2+ ions, which eventually causes flattening and rupture of attached liposomes as observed by in situ SFM."
|4.||Lipase (Acid Lipase)
|10.||Intravenous Immunoglobulins (IVIG)
|1.||Photochemotherapy (Photodynamic Therapy)
|3.||Dry Powder Inhalers
|4.||Fluid Therapy (Oral Rehydration Therapy)
|5.||Induced Hyperthermia (Thermotherapy)